PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
Go back to PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program| PTC THERAPEUTICS (NASDAQ: PTCT) | Delayed: 67.77 -1.04 (1.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $68.81 | 52 Week High | $35.40 | |||
| Open | $68.08 | 52 Week Low | $4.03 | |||
| Day High | $68.84 | P/E | 7.21 | |||
| Day Low | $67.58 | EPS | $9.40 | |||
| Volume | 388,488 | |||||
